Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
Homburg S, Christensen CB, Pedersen M, Sørensen SG, Donia M, Svane IM, Hendel HW, Ellebaek E. Homburg S, et al. Among authors: hendel hw. Cancers (Basel). 2024 Feb 27;16(5):964. doi: 10.3390/cancers16050964. Cancers (Basel). 2024. PMID: 38473325 Free PMC article.
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
Borch TH, Harbst K, Rana AH, Andersen R, Martinenaite E, Kongsted P, Pedersen M, Nielsen M, Kjeldsen JW, Kverneland AH, Lauss M, Hölmich LR, Hendel H, Met Ö, Jönsson G, Donia M, Svane IM. Borch TH, et al. J Immunother Cancer. 2021 Jul;9(7):e002703. doi: 10.1136/jitc-2021-002703. J Immunother Cancer. 2021. PMID: 34210820 Free PMC article.
Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
Helvind NM, Weitemeyer MB, Chakera AH, Hendel HW, Ellebæk E, Svane IM, Kjærskov MW, Bojesen S, Skyum H, Petersen SK, Bastholt L, Johansen C, Bidstrup PE, Hölmich LR. Helvind NM, et al. Among authors: hendel hw. Ann Surg Oncol. 2023 Apr;30(4):2377-2388. doi: 10.1245/s10434-022-13034-6. Epub 2023 Feb 8. Ann Surg Oncol. 2023. PMID: 36752970
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM. Andersen R, et al. Among authors: hendel hw. Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006492
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M. Andersen R, et al. Among authors: hendel hw. Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139. Ann Oncol. 2018. PMID: 29688262 Free article. Clinical Trial.
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM. Pedersen M, et al. Among authors: hendel hw. Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018. Oncoimmunology. 2018. PMID: 30524900 Free PMC article.
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: hendel hw. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887574 Free PMC article. Clinical Trial.
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: hendel hw. Nat Med. 2022 Apr;28(4):871. doi: 10.1038/s41591-022-01771-w. Nat Med. 2022. PMID: 35260843 Free PMC article. No abstract available.
72 results